Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin

Overactive bladder (OAB) is a difficult condition to live with and is very costly to the community. OAB affects 16% of the adult population and rises with increasing age. We describe the necessary steps in evaluation and behavioral therapy prior to initiating medical therapy. There are several medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Chughtai, Bilal, Levin, Robert, De, Elise
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682382/
https://www.ncbi.nlm.nih.gov/pubmed/18982920
_version_ 1782167046480461824
author Chughtai, Bilal
Levin, Robert
De, Elise
author_facet Chughtai, Bilal
Levin, Robert
De, Elise
author_sort Chughtai, Bilal
collection PubMed
description Overactive bladder (OAB) is a difficult condition to live with and is very costly to the community. OAB affects 16% of the adult population and rises with increasing age. We describe the necessary steps in evaluation and behavioral therapy prior to initiating medical therapy. There are several medications that have been used for the treatment of patients who suffer from OAB. This manuscript discusses the popular agents used for OAB, with a focus on the recent clinical trials on darifenacin.
format Text
id pubmed-2682382
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26823822009-05-20 Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin Chughtai, Bilal Levin, Robert De, Elise Clin Interv Aging Review Overactive bladder (OAB) is a difficult condition to live with and is very costly to the community. OAB affects 16% of the adult population and rises with increasing age. We describe the necessary steps in evaluation and behavioral therapy prior to initiating medical therapy. There are several medications that have been used for the treatment of patients who suffer from OAB. This manuscript discusses the popular agents used for OAB, with a focus on the recent clinical trials on darifenacin. Dove Medical Press 2008-09 2008-09 /pmc/articles/PMC2682382/ /pubmed/18982920 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Chughtai, Bilal
Levin, Robert
De, Elise
Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
title Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
title_full Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
title_fullStr Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
title_full_unstemmed Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
title_short Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
title_sort choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682382/
https://www.ncbi.nlm.nih.gov/pubmed/18982920
work_keys_str_mv AT chughtaibilal choiceofantimuscarinicagentsforoveractivebladderintheolderpatientfocusondarifenacin
AT levinrobert choiceofantimuscarinicagentsforoveractivebladderintheolderpatientfocusondarifenacin
AT deelise choiceofantimuscarinicagentsforoveractivebladderintheolderpatientfocusondarifenacin

Ejemplares similares